Forte Biosciences
FBRX
31 hedge funds and large institutions have $3.6M invested in Forte Biosciences in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 2 closing their positions.
15,900% more call options, than puts
Call options by funds: $160K | Put options by funds: $1K
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.08% less ownership
Funds ownership: 0.74% → 0.66% (-0.08%)
8% less capital invested
Capital invested by funds: $3.9M → $3.6M (-$302K)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$23.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.9K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$10.9K |
| 5 |
FIA
FNY Investment Advisers
New York
|
+$9.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$415K |
| 2 |
Millennium Management
New York
|
-$43.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$9.87K |
| 4 |
BlackRock
New York
|
-$9.43K |
| 5 |
Renaissance Technologies
New York
|
-$9.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $144 | +$26 | +1 | +20% |
|
27
Bank of America
Charlotte,
North Carolina
| $122 | -$234 | -9 | -64% |
|
|
28
UBS Group
Zurich,
Switzerland
| $34 | -$9.87K | -380 | -100% |
|
29
JP Morgan Chase
New York
| $18 | – | – | – |
|
|
NM
30
Newtyn Management
New York
| – | -$415K | -16,430 | Closed |
|
|
LFG
31
Larson Financial Group
St Louis,
Missouri
| – | -$35 | -1 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$26 | -1 | -14% |
|
FBRX Hedge Fund Activity: Q2 2023 in Review
31 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q2 2023, worth a combined $3.6M — down 7.7% from $3.9M a quarter earlier.
Fund positioning in FBRX was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 8 added to existing stakes and 9 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $23.3K. The largest seller was Newtyn Management, exiting entirely with an estimated $415K sold.
- 31 institutional investors held Forte Biosciences (FBRX) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $3.6M of Forte Biosciences stock for Q2 2023, down 7.7% quarter-over-quarter.
- 2 funds opened new Forte Biosciences positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest Forte Biosciences buyer in Q2 2023 was Citadel Advisors, an estimated $23.3K added.
- The largest Forte Biosciences seller in Q2 2023 was Newtyn Management, an estimated $415K sold.
Based on aggregated 13F filings for Q2 2023.